All In Biotech

Drug Trial Radar · NCT00171210

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload

Last checked: Nov 20, 2026Latest source record: May 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

506

Actual

Start

Oct 2004

Primary completion

Apr 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years. The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.

Conditions

  • Transfusional Iron Overload in β-thalassemia

Interventions

  • DeferasiroxDrug

    Tablets taken orally once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse EventTime frame: up to 5 years

Locations

49 sites in 12 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital and Research Center at Oakland

    Oakland, California

  • Stanford Hospital, Division of Oncology

    Stanford, California

  • Children's Memorial Hospital

    Chicago, Illinois

  • Children's Hospital Boston, Dept of Hematology

    Boston, Massachusetts

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Laken, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Mons, Belgium

  • Novartis Investigative Site

    Campinas, Brazil

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Montreal, Canada

  • Novartis Investigative Site

    Toronto, Canada

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Düsseldorf, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Ioannina, Greece

  • Novartis Investigative Site

    Pátrai, Greece

  • Novartis Investigative Site

    Thessaloniki, Greece

  • Novartis Investigative Site

    Brindisi, Italy

  • Novartis Investigative Site

    Cagliari, Italy

  • Novartis Investigative Site

    Catania, Italy

  • Novartis Investigative Site

    Ferrara, Italy

  • Novartis Investigative Site

    Genova, Italy

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    Monza, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Palermo, Italy

  • Novartis Investigative Site

    Pavia, Italy

  • Novartis Investigative Site

    Roma, Italy

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.